108 Denosumab in men with non-metastatic castration-resistant prostate cancer (CRPC) and PSA doubling time (PSADT) ≤6 months

Autor: Miller, K., Smith, M.R., Dearnaley, D., Dogliotti, L., Egerdie, B., Fizazi, K., Kueppers, F., Montes De Oca, L., Morote, J., Pavlik, I., Sieber, P., Tammela, T.L., Van Poppel, H., Wirth, M., Wong, S., Ye, Z., Braun, A.
Zdroj: In European Urology Supplements March 2013 12(1):e108-e109
Databáze: ScienceDirect
Externí odkaz: